MINK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL234334	1.00	5/20
SCHEMBL232042	1.00	4/20
SCHEMBL147422	0.66	4/20
SCHEMBL144979	0.56	4/20
Linifanib (SCHEMBL93804)	1.00	3/20
SCHEMBL299518	0.76	3/20
SCHEMBL146734	0.67	3/20
SCHEMBL144651	0.67	3/20
SCHEMBL146677	0.67	3/20
SCHEMBL144378	0.66	3/20
SCHEMBL142020	0.65	3/20
SCHEMBL148704	0.62	3/20
SCHEMBL147730	0.61	3/20
SCHEMBL148478	0.61	3/20
SCHEMBL144118	0.61	3/20
SCHEMBL144615	0.61	3/20
SCHEMBL147715	0.61	3/20
SCHEMBL143818	0.61	3/20
SCHEMBL143827	0.59	3/20
SCHEMBL145924	0.59	3/20

Clinical trials — most relevant to MINK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pharmacogenomic Evaluation of Antihypertensive Responses	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)	PHASE2/PHASE3	COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer	PHASE1	UNKNOWN
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
Screening for Genetic Forms of Diabetes in Convention of Care for Children and Adolescents With Diabetes (GENEPEDIAB)	nan	COMPLETED
Identifying Maturity-onset Diabetes of the Young in Emirati Patients	nan	NOT_YET_RECRUITING
DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma	nan	COMPLETED
Predisposition Genes in Monogenic Diabetes (DIAMONO)	nan	COMPLETED
Monogenic Diabetes Misdiagnosed as Type 1	nan	RECRUITING
Genomic Study of Young-Onset Diabetes Mellitus	nan	UNKNOWN
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Dried Fruit and Postprandial Glycemia Trial	nan	UNKNOWN
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.	nan	COMPLETED
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease	nan	COMPLETED
Serum DCAMKL1 Pre and Post Treatment in Patients With Pancreatic Cancer	nan	ACTIVE_NOT_RECRUITING
The Influence of Genetic Variations in ELAPOR1 or ELAPOR2 on Insulin Secretion and Glucose Regulation in Humans	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MINK1 binder may also engage these)

Protein	Name	Similarity
F1LP90	—	1.000	F1LP90 →
Q9JM52	—	1.000	Q9JM52 →
TNIK	TRAF2 and NCK-interacting protein kinase	0.998	landscape →
P97820	—	0.998	P97820 →
MAP4K4	Mitogen-activated protein kinase kinase kinase kinase 4	0.998	landscape →
P83510	—	0.997	P83510 →
F1QIC4	—	0.995	F1QIC4 →
Q6PEI3	—	0.995	Q6PEI3 →
Q80TZ9	—	0.995	Q80TZ9 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.994	landscape →
Q62901	—	0.993	Q62901 →
BMP2K	BMP-2-inducible protein kinase	0.993	landscape →
A7MBB4	—	0.993	A7MBB4 →
CDKL5	Cyclin-dependent kinase-like 5	0.993	landscape →
Q63553	—	0.993	Q63553 →
Q6NSM8	—	0.993	Q6NSM8 →
Q3ULB5	—	0.992	Q3ULB5 →
Q5R8X7	—	0.992	Q5R8X7 →
Q5TZ18	—	0.992	Q5TZ18 →
Q148W8	—	0.992	Q148W8 →
B1AZP2	—	0.992	B1AZP2 →
Q6C3D7	—	0.992	Q6C3D7 →
Q9H329	—	0.992	Q9H329 →
Q5HZJ0	—	0.991	Q5HZJ0 →
Q9H1K0	—	0.991	Q9H1K0 →
Q66J90	—	0.991	Q66J90 →
Q9EQZ7	—	0.991	Q9EQZ7 →
Q86TC9	—	0.991	Q86TC9 →
Q5VZP5	—	0.991	Q5VZP5 →
Q2EJA0	—	0.991	Q2EJA0 →